D. Boral Capital reissued their buy rating on shares of VolitionRx (NYSE:VNRX – Free Report) in a report issued on Tuesday morning,Benzinga reports. They currently have a $5.00 target price on the stock.
VNRX has been the topic of several other research reports. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com initiated coverage on shares of VolitionRx in a research report on Tuesday. They set a “sell” rating on the stock.
Read Our Latest Report on VolitionRx
VolitionRx Stock Performance
Insider Buying and Selling at VolitionRx
In other VolitionRx news, Director Guy Archibald Innes purchased 174,764 shares of the company’s stock in a transaction on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the purchase, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. The trade was a 39.51 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Cameron John Reynolds purchased 139,811 shares of the company’s stock in a transaction on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, with a total value of $79,692.27. Following the purchase, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 358,266 shares of company stock valued at $204,212 over the last quarter. 12.80% of the stock is owned by company insiders.
Hedge Funds Weigh In On VolitionRx
A number of institutional investors and hedge funds have recently modified their holdings of VNRX. Lagoda Investment Management L.P. grew its stake in shares of VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Millennium Management LLC acquired a new position in shares of VolitionRx during the fourth quarter worth $36,000. Two Sigma Securities LLC acquired a new position in shares of VolitionRx during the fourth quarter worth $29,000. Finally, Northern Trust Corp grew its stake in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Stories
- Five stocks we like better than VolitionRx
- There Are Different Types of Stock To Invest In
- GitLab: Get In While It’s Down—Big Rebound Ahead
- What is the Hang Seng index?
- Tesla Stock: Finding a Bottom May Take Time
- Most Volatile Stocks, What Investors Need to Know
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.